Back to Agenda
Session 1: Patients are waiting: Health Authority regulators, WHO and Industry approaches to accelerate patients’ access to innovation
Session Chair(s)
Catherine Al Ashram
VP Regulatory Affairs & PV, Latin America MEA and Russia, Organon, Jordan
Jeffrey Kemprecos
CGA Director-Gulf, Glaxosmithkline, United Arab Emirates
Session 1: Patients are waiting: Health Authority Regulators, WHO and Industry approaches to accelerate patients’ access to innovation
Speaker(s)
Samvel Azatyan, MD, PHD
Senior Adviser, Council For International Organizations of Medical Sciences (CIOMS), Switzerland
Putting Reliance into Practice: WHO’s Activities on Regulatory Systems Strengthening
Lenita Lindström, LLM
ICH Assembly Chair and Senior Expert, European Commission, European Commission, Belgium
The ICH perspective
Mohamed Omar
Associate Director, IQVIA, Egypt
Access to Innovative Medicines: Study Comparing Regulatory Timelines in 10 Countries in the Middle East & Africa
Inas Chehimi
Head Regulatory Affairs - Middle East & North Africa, Novartis Pharma Services AG, United Arab Emirates
The Reliance Model Implementation in Practice: Examples from Jordan, Saudi Arabia and Egypt - Introduction
Heba Nabil
Chair-Egypt RWG EFPR & Regulatory Sciences Director- Egypt & Sudan, Pfizer, Egypt
The Reliance Model Implementation in Practice: Example from Egypt
Wesal Al Haqish
Drug Directorate Director, Jordan Food and Drug Administration (JFDA), Jordan
The Reliance Model Implementation in Practice: Example from Jordan
Bandar Al Hammad, MPHARM
Chief Pharmacist & Director of Veterinary Products Department, Saudi Food and Drug Authority (SFDA), Saudi Arabia
The Reliance Model Implementation in Practice: Example from Saudi Arabia
Have an account?